Clinical study of effect of ezetimibe combined with statins on residual lipoprotein cholesterol and MACE events in patients undergoing emergency intervention with acute coronary syndrome
10.12092/j.issn.1009-2501.2021.09.011
- Author:
Yifan DENG
1
;
Yifan DENG
2
;
Shenghu HE
2
;
Daxin WANG
2
;
Chengye DAI
2
;
Xiaoting XU
2
;
Jing ZHANG
2
;
Chengye DAI
3
;
Xiaoting XU
3
Author Information
1. Medical College of Yangzhou University
2. Department of Cardiovascular Medicine, Clinical Medical College of Yangzhou University, Subei People's Hospital of Jiangsu Province
3. Dalian Medical University
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Emergency interventional treatment;
Ezetimide;
Major adverse cardiac event;
Residual lipoprotein
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2021;26(9):1048-1052
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the effect of ezetimibe combined with statins on residual lipoprotein-cholesterol (RLP-C) levels and major cardiovascular adverse events (MACE) in patients with acute coronary syndrome (ACS) after emergency intervention (PCI). METHODS: A total of 90 hospitalized patients with ACS and undergoing emergency PCI were randomly divided into two groups: 48 patients in the control group received atorvastatin, and 42 patients in the study group were additionally treated with ezetimibe. RLP-C level before and after treatment was detected. The occurrence of MACE events and adverse drug events during the treatment were obtained through regular follow-up. RESULTS: Compared with the control group, the level of RLP-C in the study group was significantly decreased (P<0.05), the incidence of MACE were significantly decreased (P<0.05), and adverse drug events were not increased. CONCLUSION: The combination therapy of ezedemibe and statins can reduce RLP-C level and MACE in ACS patients undergoing emergency PCI with less adverse reactions, which is worthy of promotion and application.
